视窗
loading...
Your position:www.healthoo.com >> EN >> EN >> Pharmaceutical News >> Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years >> article
 
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Editor:xuezhe     Clicks:20    Date:2025/4/15 15:47:36
Keyword: Novartis
Healthoo Information:
Novartis plans to expits US-based manufacturing R&D footprint with a total investment of $23B over the next 5 years
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName 
Contact:  Title: Mr.Ms.
Password  
Repeat password: 
Mobile 
Email 
Verification code: 
Company Name 
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68012929
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Jiuzhou to acquire Suzhou Novartis
  • Market share of different Valsartan brands
  • Novartis stable development in China in ...
  • Novartis gets 85% stake of Zhejiang Tian...
  • Huahai and Novartis signed the agreement ...
  • Novartis hypertension drug gets Chinese appro...
  • Novartis Jiangsu API base put into opera...
  • Novartis to buy majority stake of Zhejia...
  • Novartis to invest  Times="10".25 bn on China&nbs...
  • The third largest research centre settled&nbs...
  • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463